|
|
|
|
|
Last Trade
|
Last Trade:
$73.63
|
Change:
3.32 (4.72%)
|
Trade Time:
04:00 PM EST
|
Market Cap:
$1.26B
|
|
|
|
|
|
|
Description of Business
|
|
Our business is focused on acquiring or funding programs and technologies that
pharmaceutical companies use to discover and develop medicines. Our business
model provides a diversified portfolio of biotech and pharmaceutical product
revenue streams that are supported by an efficient and low corporate cost
structure. The biotechnology industry is characterized by a binary clinical
risk, in that, either a drug candidate is successfully developed and receives
regulatory marketing approval, or the drug candidate fails in clinical trials.
Our goal is to offer investors an opportunity to participate in the promise of
the biotech industry in a profitable and diversified manner while mitigating the
binary clinical risk associated with developing a single program.
Our business model is focused on funding mid to late-stage drug development in
return for economic rights and out-licensing our technology platforms to help
partners discover and develop medicines.
|
|
|
|